Literature DB >> 20197381

Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration.

Malgorzata M Ptaszynska1, Michael L Pendrak, Mary L Stracke, David D Roberts.   

Abstract

Important roles for vascular endothelial growth factor (VEGF) and autotaxin (ATX) have been established for embryonic vasculogenesis and cancer progression. We examined whether these two angiogenic factors cooperate in regulation of endothelial cell migratory responses. VEGF stimulated expression of ATX and LPA1, a receptor for the ATX enzymatic product lysophosphatidic acid (LPA), in human umbilical vein endothelial cells. Knockdown of ATX expression significantly decreased mRNA levels for the receptors LPA1, LPA2, S1P1, S1P2, S1P3, and VEGFR2 and abolished cell migration to lysophosphatidylcholine, LPA, recombinant ATX, and VEGF. Migration to sphingosylphosphorylcholine and sphinogosine-1-phosphate was also reduced in ATX knockdown cells, whereas migration to serum remained unchanged. Furthermore, ATX knockdown decreased Akt2 mRNA levels, whereas LPA treatment strongly stimulated Akt2 expression. We propose that VEGF stimulates LPA production by inducing ATX expression. VEGF also increases LPA1 signaling, which in turn increases Akt2 expression. Akt2 is strongly associated with cancer progression, cellular migration, and promotion of epithelial-mesenchymal transition. These data show a role for ATX in maintaining expression of receptors required for VEGF and lysophospholipids to accelerate angiogenesis. Because VEGF and ATX are upregulated in many cancers, the regulatory mechanism proposed in these studies could apply to cancer-related angiogenesis and cancer progression. These data further suggest that ATX could be a prognostic factor or a target for therapeutic intervention in several cancers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20197381      PMCID: PMC2841699          DOI: 10.1158/1541-7786.MCR-09-0288

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  64 in total

1.  Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells.

Authors:  M Morales-Ruiz; M J Lee; S Zöllner; J P Gratton; R Scotland; I Shiojima; K Walsh; T Hla; W C Sessa
Journal:  J Biol Chem       Date:  2001-03-06       Impact factor: 5.157

2.  Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells.

Authors:  S W Nam; T Clair; C K Campo; H Y Lee; L A Liotta; M L Stracke
Journal:  Oncogene       Date:  2000-01-13       Impact factor: 9.867

3.  Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration.

Authors:  S Dimmeler; E Dernbach; A M Zeiher
Journal:  FEBS Lett       Date:  2000-07-21       Impact factor: 4.124

4.  Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor.

Authors:  S W Nam; T Clair; Y S Kim; A McMarlin; E Schiffmann; L A Liotta; M L Stracke
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

Review 5.  Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1).

Authors:  M Shibuya
Journal:  Int J Biochem Cell Biol       Date:  2001-04       Impact factor: 5.085

6.  Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants.

Authors:  H Gille; J Kowalski; B Li; J LeCouter; B Moffat; T F Zioncheck; N Pelletier; N Ferrara
Journal:  J Biol Chem       Date:  2000-10-31       Impact factor: 5.157

7.  Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt.

Authors:  M Morales-Ruiz; D Fulton; G Sowa; L R Languino; Y Fujio; K Walsh; W C Sessa
Journal:  Circ Res       Date:  2000-04-28       Impact factor: 17.367

8.  Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction.

Authors:  G P van Nieuw Amerongen; M A Vermeer; V W van Hinsbergh
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-12       Impact factor: 8.311

9.  Sphingosine-1-phosphate and lysophosphatidic acid stimulate endothelial cell migration.

Authors:  T S Panetti; J Nowlen; D F Mosher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-04       Impact factor: 8.311

10.  Microarray analysis identifies Autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun.

Authors:  Elizabeth J Black; Timothy Clair; Jeffrey Delrow; Paul Neiman; David A F Gillespie
Journal:  Oncogene       Date:  2004-03-25       Impact factor: 9.867

View more
  31 in total

1.  Endogenous vascular endothelial growth factor-A (VEGF-A) maintains endothelial cell homeostasis by regulating VEGF receptor-2 transcription.

Authors:  Guangqi E; Ying Cao; Santanu Bhattacharya; Shamit Dutta; Enfeng Wang; Debabrata Mukhopadhyay
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

Review 2.  New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors.

Authors:  Ross Corriden; Paul A Insel
Journal:  Purinergic Signal       Date:  2012-04-15       Impact factor: 3.765

3.  Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis.

Authors:  Sue-Chin Lee; Yuko Fujiwara; Jianxiong Liu; Junming Yue; Yoshibumi Shimizu; Derek D Norman; Yaohong Wang; Ryoko Tsukahara; Erzsebet Szabo; Renukadevi Patil; Souvik Banerjee; Duane D Miller; Louisa Balazs; Manik C Ghosh; Christopher M Waters; Tamas Oravecz; Gabor J Tigyi
Journal:  Mol Cancer Res       Date:  2014-08-26       Impact factor: 5.852

4.  Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.

Authors:  Shih-Chi Su; Xiaoxiao Hu; Patrick A Kenney; Megan M Merrill; Kara N Babaian; Xiu-Ying Zhang; Tapati Maity; Shun-Fa Yang; Xin Lin; Christopher G Wood
Journal:  Clin Cancer Res       Date:  2013-10-11       Impact factor: 12.531

5.  Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.

Authors:  Mandi M Murph; Guowei W Jiang; Molly K Altman; Wei Jia; Duy T Nguyen; Jada M Fambrough; William J Hardman; Ha T Nguyen; Sterling K Tran; Ali A Alshamrani; Damian Madan; Jianxing Zhang; Glenn D Prestwich
Journal:  Bioorg Med Chem       Date:  2015-07-02       Impact factor: 3.641

6.  Insulin-like growth factor 1 (IGF-1) stabilizes nascent blood vessels.

Authors:  Sarah Melissa P Jacobo; Andrius Kazlauskas
Journal:  J Biol Chem       Date:  2015-01-06       Impact factor: 5.157

Review 7.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

Review 8.  Role of autotaxin in cancer stem cells.

Authors:  Dongjun Lee; Dong-Soo Suh; Sue Chin Lee; Gabor J Tigyi; Jae Ho Kim
Journal:  Cancer Metastasis Rev       Date:  2018-09       Impact factor: 9.264

9.  Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.

Authors:  Lauren P Saunders; Wenxiang Cao; William C Chang; Ronald A Albright; Demetrios T Braddock; Enrique M De La Cruz
Journal:  J Biol Chem       Date:  2011-06-30       Impact factor: 5.157

10.  Lysophosphatidic acid acts on LPA1 receptor to increase H2 O2 during flow-induced dilation in human adipose arterioles.

Authors:  Dawid S Chabowski; Andrew O Kadlec; Karima Ait-Aissa; Joseph C Hockenberry; Paul J Pearson; Andreas M Beyer; David D Gutterman
Journal:  Br J Pharmacol       Date:  2018-10-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.